U.S. FDA Approves RINVOQ As A Once-Daily Pill For Moderately To Severely Active Crohn's Disease In Adults
Portfolio Pulse from Happy Mohamed
The U.S. FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active Crohn's disease. This marks the seventh FDA approval for RINVOQ across gastroenterology, rheumatology, and dermatology.
May 18, 2023 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's RINVOQ receives FDA approval for treating adults with moderately to severely active Crohn's disease, expanding its range of indications.
The FDA approval of RINVOQ for treating Crohn's disease in adults is a positive development for AbbVie. This expands the range of indications for RINVOQ, which has already been approved for use in other fields such as gastroenterology, rheumatology, and dermatology. This is likely to increase the demand for RINVOQ and potentially boost AbbVie's revenues, leading to a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100